OBJECTIVE: Around 7-10% of endometrial carcinomas are characterized by polymerase-ε-(POLE) exonuclease-domain-mutations, an ultra-mutated-phenotype and a favorable prognosis. It is currently unknown whether POLE ultra-mutated-tumors are more immunogenic when compared to the other groups of endometrial cancers. METHODS: We used autologous-dendritic-cells (DC) pulsed with whole-tumor-extracts to assess the level of CD8+ and CD4+ T-cell-activation induced by POLE-ultramutated (+) and POLE wild-type (-) endometrial cancer cells in vitro. T-lymphocyte-proliferations were evaluated using CFSE and/or ([3H])thymidine-incorporation-assays while the ability to specifically kill autologous-tumor-cells by cytotoxic-T-lymphocyte (CTL) was tested in standard 4-h-(51)Cr-cytotoxicity-assays. In order to correlate cytotoxic activity and proliferation by CD4+ and CD8+ T-lymphocytes, respectively, with a particular lymphoid subset, two-color-flow-cytometric analysis of intracellular-cytokine-expression (IFN-γ vs IL-4) at the single cell level was also performed. RESULTS: DC-pulsed with tumor extracts were able to induce CTL-responses against autologous-tumor-cells in both POLE (+) and POLE (-) cancer patients (P=0.305). These CD8+ T-cell-populations were cytotoxic against tumor-cells but they did not lyse PHA-stimulated-autologous-lymphocytes or autologous-EBV-transformed-lymphoblastoid-control-cell-lines. In contrast, only POLE (+) tumor-lysate-pulsed-DC were able to induce significant proliferation and high IFN-γ expression (i.e., Th1-cytokine-bias) in autologous in vitro DC-stimulated CD4+ T-cells as well as naïve CD4+ and CD8+ T-cells from patients-peripheral-blood (P<0.05). CONCLUSIONS: POLE ultra-mutated-tumors are significantly more immunogenic when compared to POLE (-) tumors, in particular to the helper arm of the immune system. These data lend support to the hypothesis that the better prognosis of patients with POLE (+) tumors may at least in part be linked to their enhanced immunogenicity.
OBJECTIVE: Around 7-10% of endometrial carcinomas are characterized by polymerase-ε-(POLE) exonuclease-domain-mutations, an ultra-mutated-phenotype and a favorable prognosis. It is currently unknown whether POLE ultra-mutated-tumors are more immunogenic when compared to the other groups of endometrial cancers. METHODS: We used autologous-dendritic-cells (DC) pulsed with whole-tumor-extracts to assess the level of CD8+ and CD4+ T-cell-activation induced by POLE-ultramutated (+) and POLE wild-type (-) endometrial cancer cells in vitro. T-lymphocyte-proliferations were evaluated using CFSE and/or ([3H])thymidine-incorporation-assays while the ability to specifically kill autologous-tumor-cells by cytotoxic-T-lymphocyte (CTL) was tested in standard 4-h-(51)Cr-cytotoxicity-assays. In order to correlate cytotoxic activity and proliferation by CD4+ and CD8+ T-lymphocytes, respectively, with a particular lymphoid subset, two-color-flow-cytometric analysis of intracellular-cytokine-expression (IFN-γ vs IL-4) at the single cell level was also performed. RESULTS:DC-pulsed with tumor extracts were able to induce CTL-responses against autologous-tumor-cells in both POLE (+) and POLE (-) cancerpatients (P=0.305). These CD8+ T-cell-populations were cytotoxic against tumor-cells but they did not lyse PHA-stimulated-autologous-lymphocytes or autologous-EBV-transformed-lymphoblastoid-control-cell-lines. In contrast, only POLE (+) tumor-lysate-pulsed-DC were able to induce significant proliferation and high IFN-γ expression (i.e., Th1-cytokine-bias) in autologous in vitro DC-stimulated CD4+ T-cells as well as naïve CD4+ and CD8+ T-cells from patients-peripheral-blood (P<0.05). CONCLUSIONS: POLE ultra-mutated-tumors are significantly more immunogenic when compared to POLE (-) tumors, in particular to the helper arm of the immune system. These data lend support to the hypothesis that the better prognosis of patients with POLE (+) tumors may at least in part be linked to their enhanced immunogenicity.
Authors: Diana P English; Stefania Bellone; Carlton L Schwab; Dana M Roque; Salvatore Lopez; Ileana Bortolomai; Emiliano Cocco; Elena Bonazzoli; Sudeshna Chatterjee; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: Bo Meng; Lien N Hoang; John B McIntyre; Máire A Duggan; Gregg S Nelson; Cheng-Han Lee; Martin Köbel Journal: Gynecol Oncol Date: 2014-05-16 Impact factor: 5.482
Authors: A D Santin; P L Hermonat; A Ravaggi; M Chiriva-Internati; D Zhan; S Pecorelli; G P Parham; M J Cannon Journal: J Virol Date: 1999-07 Impact factor: 5.103
Authors: Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205
Authors: A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz Journal: J Clin Invest Date: 1995-01 Impact factor: 14.808
Authors: Tina M Albertson; Masanori Ogawa; James M Bugni; Laura E Hays; Yang Chen; Yanping Wang; Piper M Treuting; John A Heddle; Robert E Goldsby; Bradley D Preston Journal: Proc Natl Acad Sci U S A Date: 2009-09-24 Impact factor: 11.205
Authors: Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson Journal: Nat Genet Date: 2012-12-23 Impact factor: 38.330
Authors: Alessandro D Santin; Stefania Bellone; Natalia Buza; Jungmin Choi; Peter E Schwartz; Joseph Schlessinger; Richard P Lifton Journal: Clin Cancer Res Date: 2016-08-02 Impact factor: 12.531
Authors: Janice M Mehnert; Anshuman Panda; Hua Zhong; Kim Hirshfield; Sherri Damare; Katherine Lane; Levi Sokol; Mark N Stein; Lorna Rodriguez-Rodriquez; Howard L Kaufman; Siraj Ali; Jeffrey S Ross; Dean C Pavlick; Gyan Bhanot; Eileen P White; Robert S DiPaola; Ann Lovell; Jonathan Cheng; Shridar Ganesan Journal: J Clin Invest Date: 2016-05-09 Impact factor: 14.808
Authors: Caroline C Billingsley; David E Cohn; David G Mutch; Erinn M Hade; Paul J Goodfellow Journal: Int J Gynecol Cancer Date: 2016-06 Impact factor: 3.437